Effect of fenofibrate in combination with urate lowering agents in patients with gout

Korean Journal of Internal Medicine

Volumn 21, Issue 2, 2006, Pages 89-93

  Lee, You Hyun ^a   Lee, Chan Hee ^b   Lee, Jisoo ^a  

^a Ewha Womans University School of Medicine   (South Korea)

^b National Health Insurance Corporation   (South Korea)

Author keywords

Fenofibrate; Gout; Hyperlipidemia; Hyperucicemia

Indexed keywords

ALKALINE PHOSPHATASE; ALLOPURINOL; ANTILIPEMIC AGENT; BENZBROMARONE; CREATININE; FENOFIBRATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LIPIDIL SUPRA; TRIACYLGLYCEROL; URIC ACID;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFICACY; DRUG WITHDRAWAL; GOUT; HUMAN; HYPERLIPIDEMIA; LIPID BLOOD LEVEL; LIVER FUNCTION TEST; MALE; OPEN STUDY; TRIACYLGLYCEROL BLOOD LEVEL; UNSPECIFIED SIDE EFFECT; URIC ACID BLOOD LEVEL;

EID: 33748415886     PISSN: 12263303     EISSN: None     Source Type: Journal    
DOI: 10.3904/kjim.2006.21.2.89     Document Type: Article

References (24)

1. Ghei M, Mihailescu M, Levinson D. Pathogenesis of hyperuricemia: recent advances. Curr Rheumatol Rep 4:270-274, 2002
2. Dai SM, Han XH, Zhao DB, Shi YQ, Liu Y, Meng JM. Prevalence of rheumatic symptoms, rheumatoid arthritis, ankylosing spondylitis, and gout in Shanghai, China: a COPCORD study. J Rheumatol 30:2245-2251, 2003
3. Chang HY, Pan WH, Yeh WT, Tsai KS. Hyperuricemia and gout in Taiwan: results from the Nutritional and Health Survey in Taiwan (1993-96). J Rheumatol 28:1640-1646, 2001
4. Yoo B. Serum uric acid levels in Korean adult population and their correlates. J Korean Rheum Assoc 2:60-68, 1995
5. Arromlee E, Michet CJ, Crowson CS, O'Fallon WM, Gabriel SE. Epidemiology of gout: is the incidence rising? J Rheumatol 29:2403-2406, 2002
6. Takahashi S, Yamamoto T, Moriwaki Y, Tsutsumi Z, Higashino K. Impaired lipoprotein metabolism in patients with primary gout: influence of alcohol intake and body weight. Br J Rheumatol 33:731-734, 1994
7. Adkins JC, Faulds D. Micronised fenofibrate: a review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia. Drugs 54:615-633, 1997
8. Desager JP, Hulhoven R, Harvengt C. Uricosuric effect of fenofibrate in healthy volunteers. J Clin Pharmacol 20:560-564, 1980
9. Feher MD, Hepburn AL, Hogarth MB, Ball SG, Kaye AE. Fenofibrate enhances urate reduction in men treated with allopurinol for hyperuricaemia and gout. Rheumatology 42:321-325, 2003
10. Noguchi Y, Tatsuno I, Suyama K, Shibata T, Yoshida T, Otsuka Y, Fuse M, Takeo C, Saito Y. Effect of fenofibrate on uric acid metabolism in Japanese hyperlipidemic patients. J Atheroscler Thromb 11:335-340, 2004
11. Desager JP, Hulhoven R, Harvengt C. Uricosuric effect of fenofibrate in healthy volunteers. J Clin Pharmacol 2:560-564, 1980
12. Takahashi S, Moriwaki Y, Yamamoto T, Tsutsumi Z, Ka T, Fukuchi M. Effect of combination treatment using anti-hyperuricaemic agents with fenofibrate and/or losartan on uric add metabolism. Ann Rheum Dis 62:572-575, 2003
13. Bastow MD, Durrington PN, Ishola M. Hypertriglyceridemia and hyperuricemia: effect of two fibric acid derivatives (bezafibrate and fenofibrate) in a double-blind, placebo-controlled trial. Metabolism 37:217-220, 1988
14. de la Serna G, Cadarso C. Fenofibrate decreases plasma fibrinogen, improves lipid profile, and reduces uricemia. Clin Pharmacol Ther 66:166-172, 1999
15. Day AP, Feher MD, Chopra R, Mayne PD. The effect of bezafibrate treatment on serum alkaline phosphatase isoenzyme activities. Metabolism 42:839-842, 1993
16. Dohmen K, Mizuta T, Nakamuta M, Shimohashi N, Ishibashi H, Yamamoto K. Fenofibrate for patients with asymptomatic primary biliary cirrhosis. World J Gastroenterol 10:894-898, 2004
17. Ganotakis E, Tsimihodimos V, Bairaktari E, Rizos E, Athyros V, Seferiades C, Elisaf M, Effect of various fibrates on serum alkaline phosphatase activity. Atherosclerosis 165:187-188, 2002
18. Papadakis JA, Ganotakis ES, Jagroop IA, Winder AF, Mikhailidis DP. Statin+fibrate combination therapy fluvastatin with bezafibrate or ciprofibrate in high risk patients with vascular disease. Int J Cardiol 69:237-244, 1999
19. Maesaka JK, Fishbane S. Regulation of renal urate excretion: a critical review. Am J Kidney Dis 32:917-933, 1998
20. Schmidt MI, Watson RI, Duncan BB, Metcalf P, Brancati FL, Sharrett AR, Davis CE, Heiss G. Clustering of dyslipidemia, hyperuricemia, diabetes, and hypertension and its association with fasting insulin and central and overall obesity in a general population. Metabolism 45:699-706, 1996
21. Moriwaki Y, Yamamoto T, Takahashi S, Tsutsumi Z, Higashino K. Apolipoprotein E phenotypes in patients with gout: relation with hypertriglyceridemia. Ann Rheum Dis 54:351-354, 1995
22. Collantes Estevez E, Pineda Priego M. Anon Barbudo J, Sanchez Guijo P. Hyperuricemia-hyperlipidemia association in the absence of obesity and alcohol abuse. Clin Rheumatol 9:28-31, 1990
23. Tinahones JF, Perez-Lindon G, C-Soriguer FJ, Pareja A, Sanchez-Guijo P, Collantes E. Dietary alterations in plasma very low density lipoprotein levels modify renal excretion of urates in hyperuricemic-hypertriglyceridemic patients. J Clin Endocrinol Metab 82:1188-1191, 1997
24. Ledwith BJ, Pauley CJ, Wagner LK, Rokos CL, Alberts DW, Manam S. Induction of cyclooxygenase-2 expression by peroxisome proliferators and non-tetradecanoylphorbol 12, 13-myristate-type tumor promoters in immortalized mouse liver cells. J Biol Chem 272:3707-3714, 1997